Form 4: Atara Biotherapeutics Executive Jill Henrich Reports Stock Sales to Cover Tax Obligations

Jill Henrich, EVP at Atara Biotherapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Summary

• Jill Henrich, an Executive Vice President at Atara Biotherapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On August 16, 2024, Henrich sold 831 shares of common stock at $6.629 per share and 132 shares at $6.631 per share.
• These sales were executed automatically to satisfy tax withholding obligations related to the vesting of previously granted restricted stock units.
• Following the reported transactions, Henrich beneficially owns 20,378 shares of Atara Biotherapeutics stock, which includes 4,284 shares purchased under the Employee Stock Purchase Plan on May 31, 2024, and reflects the 1:25 reverse stock split effected on June 20, 2024.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing simply reports stock sales for tax purposes, a common occurrence.

Industry Context

Form 4 filings are standard practice for reporting transactions by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for publicly traded companies, ensuring transparency in insider trading activities.
• Similar filings are common across the biotechnology industry, with executives often selling shares to cover tax obligations related to equity compensation.
• Companies like Gilead Sciences, Amgen, and Biogen also see regular Form 4 filings from their executives.

Stakeholder Impact

• The stock sales by an executive could have a minor impact on shareholder sentiment, but are generally viewed as routine if for tax purposes.

Key Dates